SRAMF (Sisram Medical) Current Deferred Revenue: $0.0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SRAMF Sisram Medical Ltd SRAMF
57 GF Score
Price $0.44
GF Value $0.98
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Sisram Medical Current Deferred Revenue?

Sisram Medical SRAMF 57 Current Deferred Revenue is $0.0 Mil as of Dec. 2025. GuruFocus rates SRAMF with a GF Score™ of 57/100 and a GF Value™ of $0.98 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Sisram Medical's current deferred revenue for the quarter that ended in Dec. 2025 was $0.0 Mil.

Sisram Medical Current Deferred Revenue Related Terms

Sisram Medical Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Sisram Medical's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sisram Medical Current Deferred Revenue Chart

Sisram Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Sisram Medical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SRAMF
57GF Score
Sisram Medical Ltd SRAMF
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $0.0 Mil mean?
Sisram Medical (SRAMF) has a Current Deferred Revenue of $0.0 Mil as of Dec. 2025. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Sisram Medical and its competitors.
Is Sisram Medical's Current Deferred Revenue too high?
Sisram Medical's current Current Deferred Revenue is $0.0 Mil. Overall, Sisram Medical has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sisram Medical's Current Deferred Revenue compare to ABT and SYK?
Sisram Medical's Current Deferred Revenue of $0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Devices & Instruments company?
A good Current Deferred Revenue depends on the Medical Devices & Instruments industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Sisram Medical and its competitors. Sisram Medical's current Current Deferred Revenue is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sisram Medical stock overvalued right now?
Based on GuruFocus' analysis, Sisram Medical (SRAMF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.98, compared to a current price of $0.44 — trading 55.3% below its estimated fair value. The current Current Deferred Revenue is $0.0 Mil. Sisram Medical's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Sisram Medical (SRAMF), the current Current Deferred Revenue is $0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sisram Medical (SRAMF) Overvalued in 2026?

Based on GuruFocus' analysis, Sisram Medical stock appears to be undervalued. The current stock price of $0.44 is trading 55.3% below its estimated GF Value™ of $0.98. GuruFocus considers Sisram Medical to be Significantly Undervalued.

Key valuation signals for SRAMF:

  • Current Deferred Revenue: $0.0 Mil
  • GF Value™: $0.98 vs. price of $0.44 (55.3% below fair value)
  • GF Score™: 57/100 with 5 warning signs

No single metric tells the full story. See the SRAMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sisram Medical Business Description

Other Exchanges 01696:Hong Kong
Address HaHarash Street 18, Ofek Building 15, Industrial Park, Caesarea, ISR, 3079895
Sisram Medical Ltd is an investment holding company specializing in medical technology for healthcare. The Company is involved in research, development, design, manufacture, sale and marketing of medical aesthetics and dental equipment, home use devices, injectables and cosmeceuticals products. The company's products include Soprano Titanium, Colibri technology, and others. Some of the company's brands are Alma, Soprano, Copulla, and LMNT. It operates through the following geographical segments: North America which is its key revenue generating market, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
57GF Score

Get the complete analysis for SRAMF

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.44
Price
$0.98
GF Value